Harnessing the power of the immune system
Despite the challenges faced by researchers, understanding of autoimmune diseases is improving, largely down to advances in cell biology and laboratory techniques like DNA sequencing. More than this, we are realising that whilst breakthroughs are rare, hitting the right target in one disease has the potential to unlock doors for many, many more.
We believe that if we can harness the power of the immune system we may be able to alter the fundamental course of certain diseases, helping address a huge unmet patient need.
For example, we are testing the theory that if a treatment works in a disease driven by a particular part of the immune system, then it should work in other diseases driven by the same part of the immune system. Our strategy is to explore this further, in the hope that it’s the starting point in the development of new medicines for our patients.
But we can’t do this alone and collaboration is key. We are leading the field with the concept of building long-term collaborative relationships. Our Immunology Network, unique to GSK, embeds some of the world’s leading immunologists from academic research institutions within our labs, working alongside our scientists.
Together, we hope that this collaboration, co-operation and collective intelligence will help identify exciting new areas of research and lead us into the next 50 years of medicines’ exploration.